Aytu could prove to be a great asset for Suda if it can set the value of Zolpimist. For Aytu to increase the value of zolpimist by 800% they must see a need and a market and if it takes off then it should set an increased value for Zolpimist, globally.
ZolpiMist™ Sales May Wake You Up
Although Natesto® is the flagship product, AYTU's interest to seek out and promote novel products with serious disruptive potential is clear throughout its entire portfolio. For instance, ZolpiMist™ serves as another potential billion-dollar market opportunity for the company. Currently the only FDA-approved oral spray prescription sleep aid available on the market, ZolpiMist™ is a fast-acting formulation of zolpidem tartrate, a commonly prescribed sleep medication you may know as Ambien.
Like other AYTU products, being different can be better, and the nasal application of ZolpiMist™ has demonstrated a clinically significant increase in onset of action when compared to the pill form. For its patients struggling with insomnia characterized by difficulties initiating sleep, a faster-acting treatment is a godsend – and perhaps this nasally administered form of Ambien would've helped late-night “authors” that send out those career-ending tweets fall asleep quicker, and not blame the pill for its slow acting formulation.
Easy to use, effective, and as good or better than Ambien, ZolpiMist™, too, has extraordinary potential once the product gains traction. Launched just a couple of months ago, investors are looking forward to initial reports of product sales that will likely get a boost from an already trained and mobile sales force that is promoting Natesto® in offices around the country.
